Back

Long-term efficacy of mavacamten on health status in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: results from long-term extension of the EXPLORER-CN trial

19 May 2025 (16:00 - 17:00)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (3) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Michael Hurst

Cardiff (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Mavacamten eligibility in an Irish hypertrophic cardiomyopathy cohort
Mr P. Kopp (Stony Brook, US)
Abstract Slides Video
Presentation thumbnail
Usefulness of implantable loop recorders in patients with hypertrophic cardiomyopathy
Doctor M. Figueiredo (Barreiro, PT)
Abstract Slides Video
Presentation thumbnail
Medical education significantly improves the recognition of red flags of transthyretin cardiac amyloidosis
Doctor C. Rohani-Montez (London, GB)
Abstract Slides Video
Presentation thumbnail
Reduction of >100 mmHg left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy during mavacamten treatment already after one week of treatment
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Temporal changes in echocardiographic parameters of diastolic dysfunction in obstructive hypertrophic cardiomyopathy during mavacamten treatment
Doctor H. Takacs (Szeged, HU)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (3)

The Event

Event poster

Heart Failure 2025

19 May 2025 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-term efficacy and safety of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial
thumbnail
Congress Presentation
Long-term efficacy of mavacamten on cardiac structure and function in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial
thumbnail
Congress Presentation
Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources